On Thursday, Travere Therapeutics Inc (NASDAQ: TVTX) remained unchanged from the previous day of trading 2.40% from the last session, before settling in for the closing price of $14.57. Price fluctuations for TVTX have ranged from $5.12 to $25.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 13.83%. Company’s average yearly earnings per share was noted 68.73% at the time writing. With a float of $87.44 million, this company’s outstanding shares have now reached $87.45 million.
The extent of productivity of a business whose workforce counts for 385 workers is very important to gauge. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Travere Therapeutics Inc is 1.50%, while institutional ownership is 109.06%. The most recent insider transaction that took place on Apr 11 ’25, was worth 631. In this transaction CHIEF FINANCIAL OFFICER of this company sold 48 shares at a rate of $13.14, taking the stock ownership to the 89,990 shares. Before that another transaction happened on Apr 11 ’25, when Company’s Officer proposed sale 48 for $13.14, making the entire transaction worth $631.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.73% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Check out the current performance indicators for Travere Therapeutics Inc (TVTX). In the past quarter, the stock posted a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 1.02 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
The latest stats from [Travere Therapeutics Inc, TVTX] show that its last 5-days average volume of 1.34 million was inferior to 1.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 55.14%. Additionally, its Average True Range was 1.21.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 16.24%, which indicates a significant decrease from 31.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.65% in the past 14 days, which was higher than the 60.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.33, while its 200-day Moving Average is $16.03. Now, the first resistance to watch is $15.09. This is followed by the second major resistance level at $15.27. The third major resistance level sits at $15.53. If the price goes on to break the first support level at $14.65, it is likely to go to the next support level at $14.39. Assuming the price breaks the second support level, the third support level stands at $14.21.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are currently 88,772K shares outstanding in the company with a market cap of 1.32 billion. Presently, the company’s annual sales total 233,180 K according to its annual income of -321,550 K. Last quarter, the company’s sales amounted to 74,790 K and its income totaled -60,260 K.
